VFA
BOLD

Valeo Financial Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

Valeo Financial Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-81
Closed -$3K – 1729
2019
Q2 		$3K Hold
81
– – ﹤0.01% 1368
2019
Q1 		$3K Buy
+81
New +$2.32K ﹤0.01% 1321

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Valeo Financial Advisors's BOLD Position: Q3 2019 in Review

Valeo Financial Advisors sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2019, closing a stake of 81 shares — an estimated $3K sold.

Valeo Financial Advisors first reported a position in BOLD in Q1 2019 and held it in 2 quarters. The position peaked at $3K in Q2 2019. 149 funds tracked by Wall St. Rank hold BOLD as of Q3 2019.

  • Valeo Financial Advisors reported no remaining Audentes Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
  • Valeo Financial Advisors sold 81 Audentes Therapeutics, Inc shares in Q3 2019, an estimated $3K.
  • Valeo Financial Advisors first reported a position in Audentes Therapeutics, Inc in Q1 2019 and held it in 2 quarters.
  • Valeo Financial Advisors's Audentes Therapeutics, Inc position peaked at $3K in Q2 2019.
  • 149 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2019.

Based on Valeo Financial Advisors's 13F filing for Q3 2019, filed 15 Oct 2019.